{"schema_version":"secwatch.filing_event.v1","accession":"0001619856-24-000046","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2024-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.280145+00:00","generated_at":"2026-06-01T06:49:32.000295+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Caribou Biosciences reports CB-010 ANTLER Phase 1 data: 14.4 mo median PFS with partial HLA matching","bullets":["Median PFS of 14.4 months with ≥4 HLA matches (N=13) vs 2.8 months with ≤3 matches (N=33).","In LBCL patients with ≥4 HLA matches (N=11), median PFS not reached; ORR 91%, CR rate 36%.","No Grade ≥3 CRS or GvHD observed; RP2D selected at 80x10^6 CAR-T cells.","Plan to enroll ~20 additional 2L LBCL patients prospectively; initial data expected H1 2025.","Pivotal Phase 3 trial for CB-010 in 2L LBCL planned for H2 2025 if confirmed."],"urls":{"canonical":"https://secwatch.observer/filing/0001619856-24-000046","json":"https://secwatch.observer/filing/0001619856-24-000046.json","markdown":"https://secwatch.observer/filing/0001619856-24-000046.md","text":"https://secwatch.observer/filing/0001619856-24-000046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000161985624000046/0001619856-24-000046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000161985624000046/crbu-20240602.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:49:32.000295+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}